Icagen-T
Oro Valley, US · Founded 2016 · Delaware corporation
Founders & leadership
MK
Mark KorbExecutive
RC
Richard CunninghamExecutive
DK
Douglas KrafteExecutive
Board
TT
Timothy TysonBoard director
Reported raises · per SEC filings
Form D private placements$16M disclosed across 2 rounds · 2017–2018
▶$8MraisedSep 2018 · 1 investors · PharmaceuticalsRule 506(b)
▶$8MraisedSep 2018 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Timothy TysonDirector
- Mark KorbExecutive Officer, Director
- Douglas KrafteDirector
- Richard CunninghamExecutive Officer, Director
- Offering amount
- $8M
- Amount sold
- $8M
- First sale
- Aug 2018
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$8MraisedMay 2017 · 1 investors · BiotechnologyRule 506(b)
▶$8MraisedMay 2017 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mark KorbExecutive Officer, Director
- Timothy TysonDirector
- Richard CunninghamExecutive Officer, Director
- Douglas KrafteDirector
- Offering amount
- $8M
- Amount sold
- $8M
- First sale
- May 2017
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- How much funding has Icagen-T raised?
- Icagen-T has disclosed $16M raised across 2 rounds.
- Where is Icagen-T headquartered?
- Icagen-T is headquartered in Oro Valley, US.